Voyager Therapeutics, Inc. (VYGR): Results of Operations and Financial Condition
Voyager Therapeutics, Inc. (VYGR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 vygr-ex99_1.htm EX-99.1 EX-99.1 Voyager Reports Second Quarter 2026 Financial and Operating Results - VY7523 clinical data and VY1706 clinical entry, both in Alzheimer’s, expected Q4 2026 - - Ended Q2 2026 with cash position of $149 million, runway into 2028 - LEXINGTON
How this was made
The 30-second read
Why it matters
The filing provides actionable updates on (1) FDA IND clearance for VY1706 enabling US trial initiation, (2) expected Q4 2026 dosing and Q4 2026 tau PET imaging efficacy data for VY7523, and (3) cash runway into 2028 based on $148.8M cash and marketable securities at June 30, 2026.
Market read
Traders can update probability-weighted timelines for VY1706 and VY7523 based on reiterated Q4 2026 milestones and the newly cleared IND, while also monitoring cash runway and burn trajectory.
What to watch
Collaboration revenue declined to $3.2M in Q2 2026 and R&D spend fell; traders may watch whether cost reductions or partner-driven transitions affect future burn and milestone funding.
Background
This is Voyager Therapeutics’ SEC Form 8-K (Item 2.02) with Q2 2026 financials and operating highlights for its Alzheimer’s tau programs and other pipeline items.
Ticker impact
Voyager’s 8-K reports Q2 2026 results plus new clinical/regulatory milestones, including FDA IND clearance for VY1706 and expected dosing in Q4 2026.
Moderate positive bias, with volatility around Q4 2026 milestone expectations and any follow-on updates on enrollment and data readouts.
The filing is a primary disclosure (8-K) with concrete dates (Q4 2026 dosing and tau PET data) and a fresh FDA clearance enabling trial initiation, which can re-rate probability-weighted timelines. However, it does not include new efficacy/clinical outcomes, limiting upside surprise potential.
Market effects
Reinforces investor attention on tau-targeted Alzheimer’s programs and gene therapy trial starts, which can influence sentiment across early-stage neurodegeneration peers.
Primarily US biotech sentiment; limited direct regional spillover beyond Nasdaq-listed small/mid-cap biotech flows.
Health Canada CTA clearance for VY1706 supports broader North American trial execution, potentially improving enrollment expectations.
Counterpoint
Cash runway into 2028 and milestone timing may already be partially priced; without new clinical efficacy or safety signals, the market may fade the update after initial reaction.
Key entities
- companyVoyager Therapeutics, Inc.
Nasdaq-listed biotech reporting Q2 2026 results and clinical/regulatory milestones via SEC 8-K.
- programVY1706
Tau silencing gene therapy for early Alzheimer’s; FDA IND cleared, dosing expected Q4 2026.
- programVY7523
Anti-tau antibody for Alzheimer’s; tau PET imaging efficacy data expected Q4 2026.
- partnerNeurocrine Biosciences
Partner stating intent to initiate a clinical trial with NBIB-223 in H2 2026 pending FDA IND clearance.
- regulatorFDA
Cleared Voyager’s IND application for VY1706, enabling US clinical trial initiation.
